Healthcare Italian Community

Amplifon’s hearing-aid retail model faces growing pressure as shoppers move online and big tech pushes simpler, more accessible devices that could weaken pricing and customer loyalty. At the same time, cost-cutting, acquisitions, and an aging population could still support a comeback—making the next phase a test of whether it can adapt fast enough.Read more

DiaSorin could surprise investors if its testing platforms win more U.S. hospital contracts and its newer molecular tests become a go-to choice for large labs, helping it grow faster than many expect. The flip side is that tougher pricing rules, a reliance on older product lines, and fast-moving new technologies could squeeze profits and slow momentum.Read more

Amplifon sells hearing solutions, and the market has soured as shoppers hold back and replacement timing gets messy in parts of Europe. A new cost-cutting plan, industry buyouts, and friendlier rules could help it bounce back—but heavy reliance on Southern Europe, high debt, and slow moves into remote care could still derail the recovery.Read more

DiaSorin is pushing deeper into North American hospitals and rolling out newer, more specialized tests, aiming to keep growing even as healthcare systems get tighter on costs. The key question is whether smarter manufacturing and steady innovation can protect profits from tough pricing pressure, regulation, and fast-moving rivals.Read more

GVS is betting that new filtration products in healthcare and life sciences—and newer uses like hydrogen membranes—can carry growth even while its mobility business stays weak. The real question is whether factory ramps, customer rollouts, and regulatory approvals arrive on time, or whether delays and pricing pressure keep results stuck.Read more

GVS is shifting from a patchwork of plants and products to a tighter, more scalable setup, with transfusion medicine moving in-house and new medical and life science offerings aimed at lifting growth and profitability. The big question is whether clean-energy and electric-vehicle filtration can add meaningful momentum while weaker legacy areas and integration hiccups don’t hold the business back.Read more

DiaSorin faces a squeeze as hospitals and labs push harder on prices and more testing shifts away from big lab machines, putting its long-standing products under pressure. See why some analysts think even with cost cuts and new specialty tests, the business may struggle to meet today’s expectations.Read more

Trade tensions, tighter rules, and new rival technologies could make it harder for EL.En to sell its laser systems abroad and keep costs under control. But the business also has multiple growth engines—new products, expanding capacity, and repeat sales from consumables—that could keep it resilient if demand holds up.Read more

Amplifon could benefit as more people need help with hearing and become more comfortable buying and managing care through digital channels, giving the company a chance to keep customers longer and spend more over time. The big question is whether its store-based model can adapt fast enough as cheaper, direct-to-consumer options and new tech rivals change how people shop for hearing care.Read more